STOCK TITAN
  1. Home
  2. News
  3. VNDA

Vanda Pharmaceuticals Inc - VNDA STOCK NEWS

Welcome to our dedicated news page for Vanda Pharmaceuticals (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vanda Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vanda Pharmaceuticals's position in the market.

News
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has received a notice of allowance for its PONVORY® patent application, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis. Vanda intends to list this patent in the U.S. FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. PONVORY® is approved by the U.S. FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
News
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) announced the publication of a pivotal phase III study on the efficacy of tradipitant in treating gastroparesis in adults. The study, published in the Clinical Gastroenterology and Hepatology Journal, follows a previous study in 2021. The FDA has set a decision date for September 18, 2024, for the New Drug Application for tradipitant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
clinical trial
-
News
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced that the FDA has approved the Investigational New Drug application to evaluate VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S. This rare subtype of CMT has no available treatment, and the estimated prevalence of the CMT2S variant is less than 1 in 1,000,000 worldwide. VCA-894A is a novel antisense oligonucleotide that specifically targets a cryptic splice site variant within the IGHMBP2 gene, which plays a pivotal role in the manifestation of CMT2S. The treatment aims to enable personalized medicine and modulate gene expression for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
fda approval
News
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has received a partial denial from the United States Court of Federal Claims for the FDA's uncompensated taking of Vanda's trade secrets and confidential information. The claim filed in May 2023 seeks compensation for the FDA's improper communication and disclosure of trade secrets to certain generic drug manufacturers. The Court's decision on January 18, 2024, allows Vanda's takings claim to move forward, with the company now intending to engage in discovery to support its claims.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
Rhea-AI Summary
Vanda Pharmaceuticals Inc. announced the publication of a study on the efficacy and safety of Iloperidone in treating bipolar mania, submitted to the FDA as part of a new drug application for Fanapt. The FDA has set a target action date of April 2, 2024, for its decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) Submits Comment Letter on FDA's Draft Guidance Document
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
News
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to present at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
News
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen). PONVORY® is approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis. In a clinical study, PONVORY® showed superiority to another approved drug for MS and was associated with fewer MRI lesions. It has a proven safety profile with over 10 years of data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
acquisition
-
News
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) announced that the FDA has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. The FDA has set September 18, 2024, as the target date for its decision. If approved, tradipitant will be the first novel drug for gastroparesis in over 40 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
News
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
Rhea-AI Summary
Vanda Pharmaceuticals Inc. (VNDA) to participate in Stifel 2023 Healthcare Conference on November 14 and Jefferies 2023 London Healthcare Conference on November 16, with live access on corporate website. Investors advised to register early and access archived conferences for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
Stock VNDA logo
Vanda Pharmaceuticals Inc

Nasdaq:VNDA

VNDA Rankings

#3440 Ranked by Market Cap
#4919 Ranked by Stock Gains
N/A Ranked by Dividends

VNDA Stock Data

237.05M
52.05M
5.21%
91.5%
4.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Washington

About VNDA

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.